Fibrosis Models in Mice and Rats
Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases. To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data. Our platform also includes a clinically relevant NASH model.
Fibrosis models in mice and rats
Related Content
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
VIEW RESOURCEGouty arthritis is a common, painful inflammatory condition characterized by the deposition of monosodium urate (MSU) crystals in joints. This...
VIEW RESOURCE